Sanofi: positive results for lung cancer
(CercleFinance.com) - Sanofi announces the presentation of positive results from a phase III trial evaluating the investigational use of its Dupixent in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Meeting.
The results, published simultaneously in the NEJM, show that Dupixent was the first and only investigational biologic to achieve a significant 30% reduction in moderate to severe acute exacerbations compared to placebo.
It also significantly improved lung function at weeks 12 and 52, with numerical improvements as early as week two, and quality of life and respiratory symptoms, with numerical improvements as early as week four.
COPD is the third leading cause of death worldwide and no new drug for the treatment of this disease has been approved for over a decade, Sanofi said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.